Skip to main content
. 2021 Aug 3;22(15):8355. doi: 10.3390/ijms22158355

Figure 6.

Figure 6

Retargeting efficiency of rAAV-2E3.v6 was affected by competitors and resists heparin binding. Cells were incubated with AAV variants and competitor agents following flow cytometry analysis of GFP expression after 3 days. Data were normalized to transduction levels without competitors. (A) Comparison of bispecific antibody induced rAAV-2E3.v6 transduction of HT1080 cells expressing human or murine FAP. The fold change of GFP expression was calculated. Scattered plot and mean of two independent experiments, Mann–Whitney test, * p < 0.05. (B) Specific interaction of rAAV-2E3.v6:bispecific antibodies with FAP was analyzed in competition with increasing concentrations of BIBH1 on huFAP and (C) muFAP expressing cells. Data show mean + SD of three independent experiments, Mann–Whitney test, ** p < 0.01, ns = non-significant. (D) Specific interaction of rAAV-2E3.v6:bispecific antibodies with 2E3 epitopes was analyzed in competition with soluble 2E3 peptide. Data show mean + SD of four independent experiments, Mann–Whitney test, *** p < 0.001. (E) Specific interaction of rAAV-2E3.v6:bispecific antibodies with 2E3 epitopes was analyzed in competition with soluble 2E3 peptide mutation. Data show mean + SD of four independent experiments, Mann–Whitney test, ns = non-significant. (F) Transduction of rAAV-2E3.v4, .v5, and v.6:KiH-2E3-MO36 in comparison to AAV2 under increasing concentrations of heparin-sodium in cell culture media of HT1080 huFAP cells. Data show mean + SD of four independent experiments, Mann–Whitney test, ns = non-significant.